Mutations driving CLL and their evolution in progression and relapse

Dan A. Landau, Eugen Tausch, Amaro Taylor‐Weiner, +27

Nature

Genome InstabilitySomatic VariantGenetic DisorderGeneticsGenetic Mechanism +4

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, +29

New England Journal of Medicine

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, +21

Blood

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, +28

Blood

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, +23

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunology +12

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

Panagiotis Baliakas, Anastasia Hadzidimitriou, L-A Sutton, +28

Leukemia

Hematological MalignancyTumor BiologyRecurrent MutationsOncologyMedicine +5

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, +47

New England Journal of Medicine

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown, +20

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaOncologyMalignant Blood DisorderClinical Trials +9

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

Jeff P. Sharman, Steven Coutré, Richard R. Furman, +21

Journal of Clinical Oncology

Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia

Eugen Tausch, William Close, Anna Dolnik, +6

Haematologica

Hematological MalignancyLymphoid NeoplasiaHealth SciencesVenetoclax ResistanceImmunology +5